DRUG DISCOVERY PIPELINE
Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, drug resistant bacterial and fungal infections, and rabies, spanning over early-stage discovery to late-stage clinical trials. Click here for FNDR's areas of research focus, our publications and information about our research programs.
TUBERCULOSIS
NONTUBERCULOUS MYCOBACTERIA
BACTERIAL INFECTIONS
FUNGAL INFECTIONS
RABIES
CONTRACT SERVICES
FNDR performs various preclinical in vitro and animal studies for BSL-2 and BSL-3 bacterial, fungal and viral pathogens under a fee-for-service mode to test therapeutics, vaccines, and other items. Click here for more information.
Tuberculosis
Nontuberculous mycobacteria
Bacterial infections
Fungal infections
Viral Infections
COVID-19
Therapeutics Testing
Vaccines Testing
Virucidal Assays
In vitro Models
Animal Models
ACHIEVEMENTS
2
Drugs in Clinical Development
30+
Competitive Grants Won
8
Drug Discovery Programs
300+
Contract Research Projects Completed
4
Diagnostics & Device Programs
100+
Research and Development Partners
LATEST NEWS
FNDR’s Wastewater Device Recognized for Tackling AMR in the Environment
1 April 2025
Foundation for Neglected Disease Research has been announced as one of the nine national winners of the C-CAMP AMR Challenge 2024–25, an initiative supported by the UK Government’s Global AMR Innovation Fund (GAMRIF) under the Department of Health and Social Care. FNDR was recognized for its innovative device designed to remove antimicrobial residues from wastewater, a critical intervention targeting the environmental spread of antimicrobial resistance (AMR). The award includes support from C-CAMP and GAMRIF to further develop and scale this solution for implementation in India and low- and middle-income countries (LMICs).